Neuronetics Historical Balance Sheet
STIM Stock | USD 0.84 0.04 5.00% |
Trend analysis of Neuronetics balance sheet accounts such as Total Stockholder Equity of 35.9 M, Other Liab of 1.2 M, Net Tangible Assets of 68.9 M or Property Plant And Equipment Net of 3.9 M provides information on Neuronetics' total assets, liabilities, and equity, which is the actual value of Neuronetics to its prevalent stockholders. By breaking down trends over time using Neuronetics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Neuronetics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Neuronetics is a good buy for the upcoming year.
Neuronetics Inventory |
|
Neuronetics |
About Neuronetics Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Neuronetics at a specified time, usually calculated after every quarter, six months, or one year. Neuronetics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Neuronetics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Neuronetics currently owns. An asset can also be divided into two categories, current and non-current.
Neuronetics Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Neuronetics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Neuronetics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Neuronetics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Neuronetics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Most accounts from Neuronetics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Neuronetics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.At this time, Neuronetics' Cash is very stable compared to the past year. As of the 22nd of November 2024, Cash And Short Term Investments is likely to grow to about 69.7 M, while Short and Long Term Debt Total is likely to drop about 44.7 M.
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 39.5M | 39.7M | 62.5M | 44.7M | Total Assets | 141.2M | 116.9M | 115.8M | 100.9M |
Neuronetics balance sheet Correlations
Click cells to compare fundamentals
Neuronetics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Neuronetics balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 100.2M | 78.7M | 141.2M | 116.9M | 115.8M | 100.9M | |
Short Long Term Debt Total | 34.3M | 38.3M | 39.5M | 39.7M | 62.5M | 44.7M | |
Other Current Liab | 9.0M | 6.0M | 6.9M | 13.4M | 10.9M | 9.3M | |
Total Current Liabilities | 27.7M | 13.7M | 15.7M | 33.2M | 19.8M | 20.5M | |
Total Stockholder Equity | 47.9M | 25.5M | 85.2M | 57.1M | 34.2M | 35.9M | |
Other Liab | 2.1M | 1.7M | 1.5M | 829K | 746.1K | 1.2M | |
Net Tangible Assets | 46.7M | 25.5M | 85.2M | 57.1M | 65.6M | 68.9M | |
Property Plant And Equipment Net | 4.9M | 4.1M | 5.1M | 5.3M | 4.8M | 3.9M | |
Current Deferred Revenue | 2.2M | 2.0M | 2.5M | 2.0M | 1.6M | 2.2M | |
Net Debt | (41.4M) | (10.6M) | (54.6M) | (30.6M) | 2.8M | 2.9M | |
Retained Earnings | (250.1M) | (277.5M) | (308.7M) | (345.9M) | (376.1M) | (394.9M) | |
Accounts Payable | 4.6M | 3.7M | 4.3M | 2.4M | 4.8M | 3.8M | |
Cash | 75.7M | 49.0M | 94.1M | 70.3M | 59.7M | 68.7M | |
Non Current Assets Total | 11.7M | 13.6M | 25.9M | 18.1M | 22.0M | 13.4M | |
Non Currrent Assets Other | 5.1M | 7.2M | 19.1M | 11.6M | 8.6M | 7.4M | |
Other Assets | 5.6M | 12.9M | 167.1M | 9.2M | 1.0 | 0.95 | |
Long Term Debt | 19.9M | 34.6M | 35.3M | 22.8M | 59.3M | 34.0M | |
Cash And Short Term Investments | 76.6M | 50.8M | 96.3M | 71.9M | 60.6M | 69.7M | |
Net Receivables | 6.6M | 7.2M | 7.8M | 13.8M | 17.8M | 9.2M | |
Common Stock Total Equity | 177K | 186K | 191K | 273K | 314.0K | 329.6K | |
Common Stock Shares Outstanding | 18.4M | 18.8M | 25.5M | 26.9M | 28.7M | 17.5M | |
Long Term Debt Total | 30.4M | 19.9M | 34.6M | 22.8M | 26.3M | 28.2M | |
Liabilities And Stockholders Equity | 100.2M | 78.7M | 141.2M | 116.9M | 115.8M | 100.9M | |
Non Current Liabilities Total | 24.6M | 39.5M | 40.3M | 26.6M | 61.8M | 63.4M | |
Capital Surpluse | 291.9M | 297.8M | 302.8M | 402.7M | 463.1M | 238.9M | |
Inventory | 2.8M | 3.7M | 6.6M | 8.9M | 8.1M | 5.0M | |
Other Current Assets | 2.5M | 3.3M | 4.6M | 4.2M | 7.3M | 7.6M | |
Other Stockholder Equity | 297.8M | 302.8M | 393.6M | 402.7M | 410.0M | 274.4M | |
Total Liab | 52.3M | 53.2M | 56.0M | 59.8M | 81.6M | 78.2M | |
Property Plant And Equipment Gross | 4.9M | 4.1M | 5.1M | 5.3M | 7.6M | 4.3M | |
Total Current Assets | 88.5M | 65.0M | 115.3M | 98.8M | 93.8M | 87.4M | |
Common Stock | 186K | 191K | 264K | 273K | 291K | 190.6K | |
Property Plant Equipment | 4.9M | 730K | 5.1M | 2.0M | 2.3M | 2.7M | |
Net Invested Capital | 79M | 60.1M | 120.5M | 93.0M | 93.5M | 60.4M | |
Net Working Capital | 60.8M | 51.3M | 99.6M | 65.6M | 74.0M | 75.0M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuronetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.22) | Revenue Per Share 2.453 | Quarterly Revenue Growth (0.07) | Return On Assets (0.17) | Return On Equity (1.00) |
The market value of Neuronetics is measured differently than its book value, which is the value of Neuronetics that is recorded on the company's balance sheet. Investors also form their own opinion of Neuronetics' value that differs from its market value or its book value, called intrinsic value, which is Neuronetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuronetics' market value can be influenced by many factors that don't directly affect Neuronetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuronetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.